New Heart Stent Looks Good in Study
Xience V Experimental Drug-Coated Stent May Offer Advantages Over Current Devices
Stent May Promote Faster Healing continued...
The Xience stent also reduced reclogging of the treated arteries compared
with the standard drug-coated stent (4.7% vs. 8.9%), Stone says.
The findings should satisfy regulatory hurdles set by the FDA for approving
the device, Stone says.
In addition to Taxus, the Cypher drug-eluting stent, from Cordis Corp., a
subsidiary of Johnson & Johnson, is also approved in the U.S.
Abbott, which makes Xience, funded the research. The company is expected to
submit the data to the FDA by the end of the year.
Spencer B. King III, MD, head of interventional cardiology at Piedmont
Hospital in Atlanta, says that if approved, Xience will offer another option
for treating the more than 1 million Americans who undergo angioplasty each
That said, it won’t make the Taxus or Cypher stents obsolete, he says.
“All three stents are highly effective,” he tells WebMD. “It’s always good
to have options.”